Nymox Releases Positive New Clinical Trial Data on Durability of Response Rates to Company’s BPH Drug NX-1207
HASBROUCK HEIGHTS, N.J. (January 13, 2009)-- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today the release of positive new clinical trial data from the Company’s most recent multi-center U.S. studies of NX-1207, indicating durable benefits from Nymox’s innovative drug treatment for benign prostatic hyperplasia (BPH). In all available and eligible patients assessed at 12 months post-treatment, more than seven times as many positive responses to treatment were documented in patients who received the NX-1207 therapeutic dose as compared to patients who received the comparator finasteride (finasteride is an approved drug for BPH). In the study, positive response was defined as a 9 point or more BPH Symptom Score improvement without any subsequent BPH treatments of any kind, and corresponded to a minimum 37.5% improvement in BPH symptoms. The difference in response rate between NX-1207 and the comparator was statistically significant (p=.01). The range of improvement in individual patients who received NX-1207 and were categorized as responders was 37.5 to 93% reduction in symptoms. Overall, 76.7% of subjects who received a single dose of NX-1207 reported no further BPH treatment after 12 months (p=.01).
In the initial study, mean improvement in the NX-1207 Intent-to-Treat group at 90 days was 9.71 points (p=.001). This treatment benefit compares favorably to the mean symptom score improvement typically found after 3 months for currently approved BPH medications such as alpha blockers and 5 alpha reductase inhibitors (in the 3 to 5 point range). Patients treated with NX-1207 did not report any of the sexual side effects or the low blood pressure side effects associated with the approved drugs. Unlike currently approved BPH medications, NX-1207 treatment does not require the patient to take pills daily for the rest of his life.
NX-1207 is a novel drug developed by Nymox which is in Phase 3 development for the treatment of BPH. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs. NX-1207 is administered by a urologist in an office procedure that takes only a few minutes and involves little or no pain or discomfort.
BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. BPH causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems, and can lead to other complications.
This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
For Further Information Contact:
Nymox Pharmaceutical Corporation
Posted: January 2009